You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國衛生集團(00673.HK)附屬獲成人狂犬病毒被動免疫製劑在北京地區獨家推廣授權
中國衛生集團(00673.HK)公布,非全資附屬北京佑康與華藥集團於3月6日簽署「奧木替韋單抗注射液(迅可)推廣服務協議書」。 根據協議書,北京佑康從協議書日期至2023年12月31日期間獲得「奧木替韋單抗注射液」 在北京地區的獨家推廣服務授權,協助華北製藥在北京地區開展該藥品的相關推廣活動,包括但不限於市場調研,市場准入,學術推廣及培訓,物流配送及客戶反饋信息服務,以及其他市場需要的服務。北京佑康按照所提供的服務活動和服務標準,從華北製藥收取相關的推廣服務費。 「奧木替韋單抗注射液」是華北製藥集團自主研發的最新醫療用生物製品,用於成人狂犬病毒暴露者的被動免疫,於今年3月1日在北京地區申請上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account